CoChat

Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1‐year multicentre study

Madsbad, S., Kilhovd, B., Lager, I., Mustajoki, P., Dejgaard, A., for the Scandinavian Repaglinide Group · 2001 · Diabetic Medicine
Cited by 79

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Aims To evaluate the long‐term effectiveness and safety of repaglinide, a novel prandial glucose regulator, in comparison with glipizide in the treatment of patients with Type 2 diabetes. Methods Diet or tablet‐treated patients with Type 2 diabetes (n = 256; age 40–75 years, body mass index (BMI) 20–35 kg/m 2, HbA 1c 4.2–12.8%), without signs of severe microvascular or macrovascular complications, were included in this double‐blind, multicentre, parallel‐group comparative trial. Patients were randomized at a 2:1 ratio to repaglinide, 1–4 mg at mealtimes, or glipizide, 5–15 mg daily. Results Changes in fasting blood glucose (FBG) and HbA 1c during the 12 months of treatment showed a significant difference in favour of repaglinide. In oral hypoglycaemic agents (OHA)‐naive patients, HbA 1c decreased in the repaglinide and glipizide groups by 1.5% and 0.3%, respectively (P < 0.05 between groups). Fasting blood glucose decreased in the repaglinide group by 2.4 mmol/l and increased in the glipizide group by 1.0 mmol/l (P < 0.05 between groups). In the study population as a whole, repaglinide was able to maintain glycaemic control (HbA 1c level) during the 1‐year study period, whereas control deteriorated significantly with glipizide. Change in HbA 1c from baseline was significantly better with repaglinide than with glipizide after 12 months (P < 0.05). In addition, FBG deteriorated significantly in the glipizide group compared with the repaglinide group (P < 0.05). No patients in either group experienced a major hypoglycaemic event; the number of patients experiencing minor hypoglycaemia was similar in the repaglinide and glipizide groups (15% and 19%, respectively). Conclusions Repaglinide, given as a prandial glucose regulator, is shown to be an effective and safe treatment of patients with Type 2 diabetes, and is better than glipizide in controlling HbA 1c and FBG levels, overall, and in OHA‐naive patients. Diabet. Med. 18, 395–401 (2001)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1464-5491.2001.00490.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 79

Metadata

Authors
Madsbad, S., Kilhovd, B., Lager, I., Mustajoki, P., Dejgaard, A., & for the Scandinavian Repaglinide Group
Venue
Diabetic Medicine
Publisher
Wiley
Published
2001-05
Volume
18
Issue
5
Pages
395-401
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2132308332
Cited by
79
References
6
FWCI
4.15
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1‐year multicentre study. https://app.cochat.ai/papers/10.1046/j.1464-5491.2001.00490.x
The paper
Madsbad, S., Kilhovd, B., Lager, I., Mustajoki, P., Dejgaard, A., & for the Scandinavian Repaglinide Group. (2001). Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1‐year multicentre study. Diabetic Medicine. https://doi.org/10.1046/j.1464-5491.2001.00490.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.